Where Will Transcode Therapeutics Inc (RNAZ) Stock Go Next After It Is Down 15.15% in a Week?

Transcode Therapeutics Inc (RNAZ) stock is lower by 15.15% over the past week and gets a Bearish rating from InvestorsObserver Sentiment Indicator.

Transcode Therapeutics Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on RNAZ!

See Full RNAZ Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With RNAZ Stock Today?

Transcode Therapeutics Inc (RNAZ) stock is down -2.66% while the S&P 500 is higher by 0.63% as of 9:41 AM on Friday, Sep 29. RNAZ has fallen -$0.02 from the previous closing price of $0.58 on volume of 391,709 shares. Over the past year the S&P 500 is higher by 16.34% while RNAZ has fallen -97.48%. RNAZ lost -$24.50 per share in the over the last 12 months. To screen for more stocks like Transcode Therapeutics Inc click here.

More About Transcode Therapeutics Inc

TransCode Therapeutics Inc is an RNA oncology company. It is created to defeat the cancer through the intelligent design and effective delivery of RNA therapeutics. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others. Click Here to get the full Stock Report for Transcode Therapeutics Inc stock.